Amniox Awarded National Agreements with Premier, Inc. and The Resource Group for Birth Tissue Skin Grafting Products

By Industry News

Miami, FL – May 11, 2021 – Amniox Medical, Inc. (Amniox), a TissueTech, Inc. company and pioneer in the clinical application of human birth tissue-based products, announced today that its parent company TissueTech was awarded a group purchasing agreement with Premier, Inc. and The Resource Group on April 1, 2021. As such, members of both Group Purchasing Organizations (GPOs) can take advantage of pre-negotiated terms for Amniox human birth tissue products to support regenerative healing and functional recovery in surgical, chronic wound, and musculoskeletal applications.

These agreements afford GPO members significant opportunities to address patient needs and expeditiously facilitate optimal clinical outcomes. All included amniotic membrane and umbilical cord birth tissue products are processed using the company’s proprietary CRYOTEK® cryopreservation process to retain the tissue’s structural and functional integrity.

“We are very pleased to have been awarded contracts with two of the nation’s leading GPOs,” said TissueTech President and Chief Executive Officer Amy Tseng. “We applaud both alliances for their innovation and recognize how our agreements with Premier and The Resource Group are contributing to the delivery of high quality, cost-effective patient care.”

About Amniox Medical, Inc.
AMNIOX® Medical, Inc. is the first provider of a cryopreserved matrix comprised of human umbilical cord that can be stored in a refrigerator for up to two years and is ready to use without thawing, transplanting the benefits of regenerative healing for non-healing and chronic wounds.